CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given an average recommendation of “Hold” by the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Two ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

This income gap makes it harder for families to meet essential expenses, sometimes falling below a minimum acceptable income ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on CRSP stock, giving a Buy rating on November 6. Salim Syed’s rating is based on a combination of encouraging developments ...

CRISPR Therapeutics (NASDAQ: CRSP) is redefining medicine through its groundbreaking gene editing technology. The company has ...

Cathie Wood's ARK Innovation ETF (ARKK) has surged to its highest trading level in more than two years this week, surpassing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Robert W. Baird analyst Jack Allen has maintained their neutral stance on CRSP stock, giving a Hold rating yesterday. Jack Allen has given his ...

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ:CRSP) on Thursday, setting a price target of $166, which is ...